News & Events

Simpson Thacher is representing Morgan Stanley as financial advisor to Arch Chemicals Inc. in its sale to Lonza Group Ltd. The transaction is structured as a tender offer for 100 percent of Arch Chemicals' outstanding shares of common stock at a price of $47.20 per share in cash, representing an enterprise value of $1.4 billion. Lonza's cash offer is subject to customary conditions including the tendering of more than two-thirds of Arch Chemicals' outstanding shares of common stock and clearance from antitrust regulatory authorities. Lonza expects to complete the tender offer later in 2011.

Arch Chemicals is a global biocides company providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Arch Chemicals is listed on the New York Stock Exchange under the symbol “ARJ.”  Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries with products and services spanning from research to final product manufacture. Lonza is listed on the SIX Swiss Exchange.

The Simpson Thacher team working on this transaction includes Rob Spatt and Kevin Lehpamer.